Home/Filings/4/0001161697-24-000502
4//SEC Filing

Harper Molly 4

Accession 0001161697-24-000502

CIK 0001369568other

Filed

Dec 10, 7:00 PM ET

Accepted

Dec 11, 5:00 PM ET

Size

7.5 KB

Accession

0001161697-24-000502

Insider Transaction Report

Form 4
Period: 2024-12-09
Harper Molly
Director
Transactions
  • Exercise/Conversion

    Restricted Stock Units

    2024-12-091,413132,607 total
    Common Stock (1,413 underlying)
  • Exercise/Conversion

    Common Stock, par value $0.001 per share

    2024-12-09+1,4131,413 total
Footnotes (3)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
  • [F2]Derivative securities vest in equal tranches, 1/3rd on December 8, 2024, 1/3rd on December 8, 2025 and 1/3rd on December 8, 2026.
  • [F3]Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on December 9, 2024.

Issuer

CATALYST PHARMACEUTICALS, INC.

CIK 0001369568

Entity typeother

Related Parties

1
  • filerCIK 0001871470

Filing Metadata

Form type
4
Filed
Dec 10, 7:00 PM ET
Accepted
Dec 11, 5:00 PM ET
Size
7.5 KB